The USPSTF have continued to give screening using prostate-specific antigen (PSA) a D rating, meaning that they recommend against it. Their argument is that the harms outweigh the benefits, and at best, the benefits are small from 10 to 14 years after screening has commenced.
Many people will object to this recommendation, believing that many lives have been saved as a result of screening. The USPSTF's points are:
• First, the screening process results in pain, suffering, and a small risk for other complications.
• Second, there is a psychological consequence of receiving a false-positive test.
• Third, many of those men who are diagnosed with cancer will receive a treatment that was unnecessary, because there is still a difficulty distinguishing prostate cancers that are life-threatening from those that are indolent.
Read the commentary here: http://bit.ly/UOrZ6R
Source: Medscape
Link to the USPSTF recommendation: http://1.usa.gov/UOrBW5
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More